- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05114265
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamic Effects of KUR-101 in Healthy Adults
A Phase 1 Randomized, Double-Blind, Two Part Study of the Safety, Tolerability, Pharmacokinetics, Analgesic and Respiratory Effect of KUR-101 in Healthy Adult Participants
This project is testing the safety, tolerability, pharmacokinetics (PK, the amount of study drug in your blood) and pharmacodynamics (PD, how the study drug affects your body) of single doses of a new drug called KUR-101.
Up to 58 healthy men or women aged between 18-55 will be enrolled in this study in two parts.
Part 1 will involve a single ascending (increasing) dose (SAD) where 40 participants (5 groups of 8) will be randomised (assigned randomly, like flipping a coin) to receive a single oral dose of the study drug or placebo. The placebo will look the same as the study drug but will not contain any medicine.
Part 2: will involve a crossover design where 18 participants will be randomised to receive a single oral dose of each of three interventions (study drug, placebo or a marketed form of oxycodone). Each dose is separated by 7 days and the participants are randomised so they do not know the order of the interventions.
For Part 1 the total participation will last 9 days, of which 4 days (3 nights) will be spent in the clinic. One group of subjects in Part 1 will return to the clinic to receive a second dose of drug given with a high fat breakfast. In this group, the total participation will last 16 days, of which 8 days (7 nights) will be spent in the clinic.
For Part 2 the total participation will last 23 days, of which 9 days (8 nights) will be spent in the clinic.
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
This is a Phase 1, single-center, prospective, study of orally administered KUR-101 in normal healthy participants. The study will be conducted in two parts.
Part 1 is a randomized, double-blind, placebo-controlled study to assess the safety, tolerability, PK, analgesic and respiratory effects of single ascending doses of orally administered KUR-101 in normal healthy participants. Once the MTD has been determined, this dose, or an alternate lower dose, will be taken into Part 2 of the study.
Part 2 is a randomized, double-blind, placebo-controlled, three-period crossover study to assess the analgesic and respiratory effects of a single oral KUR-101 as compared to that of oxycodone in normal healthy participants.
Study Type
Enrollment (Actual)
Phase
- Phase 1
Contacts and Locations
Study Locations
-
-
-
Christchurch, New Zealand, 8011
- KUR-101-101 Clinical Research Site
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Healthy male and female subjects;
- Between 18 and 55 years of age;
- Provide a signed EC-approved consent form;
- Generally healthy, in the opinion of the Investigator;
- Body Mass Index (BMI) 18 to 32 kg/m^2;
- Using method of contraception;
- Willing and able to comply with protocol requirements for the duration of the study
Exclusion Criteria:
- Subjects taking prohibited medications;
- Subjects with a history or presence of clinically significant medical or psychiatric disease;
- Subjects with a history of recreational or opiate use;
- Subjects with a history of alcohol abuse or moderate to severe substance abuse;
- Subjects who have regularly used nicotine-containing products;
- Subjects with a hospital admission or major illness within 1 month prior to Screening;
- Subjects with a major surgery within 3 months prior to Screening;
- Subjects who are pregnant or breastfeeding
- Subjects who have participated (taken investigative drug and/or device) in another clinical trial within 30 days prior to Screening;
- Subjects who belong to a vulnerable population.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Sequential Assignment
- Masking: Quadruple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Part 1: Single ascending dose
Single dose of oral KUR-101 or oral placebo
|
Single oral dose of KUR-101
Single oral dose of placebo
|
Experimental: Part 2: Three-way crossover
Single dose of oral KUR-101, oral placebo and oral OxyNorm
|
Single oral dose of KUR-101
Single oral dose of placebo
Single oral dose of OxyNorm
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Part 1: Safety of KUR-101 when compared with placebo
Time Frame: From the signing of the informed consent through Day 8 in Cohort 1, 2, 4 and 5 and through Day 15 in Cohort 3
|
Measured by the incidence of treatment-emergent adverse events
|
From the signing of the informed consent through Day 8 in Cohort 1, 2, 4 and 5 and through Day 15 in Cohort 3
|
Part 2: Effect of KUR-101 on evoked pain response as compared to oxycodone and placebo
Time Frame: Up to 4 hours post dose
|
Measured using the cold pressor test
|
Up to 4 hours post dose
|
Part 2: Effect of KUR-101 on evoked pain response as compared to oxycodone and placebo
Time Frame: Up to 4 hours post dose
|
Measured using thermal sensory testing
|
Up to 4 hours post dose
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Part 1 and Part 2: Pharmacokinetics of KUR-101
Time Frame: Up to 48 hours post dose
|
Measured by levels of KUR-101 in the blood
|
Up to 48 hours post dose
|
Part 1: Pharmacokinetics of KUR-101
Time Frame: Up to 48 hours post dose
|
Measured by levels of KUR-101 in the urine
|
Up to 48 hours post dose
|
Part 1: Effect of KUR-101 on respiratory function when compared to placebo
Time Frame: Up to 8 hours post dose
|
Measured using continuous end-tidal capnography monitoring
|
Up to 8 hours post dose
|
Part 1: Effect of KUR-101 on respiratory function when compared to placebo
Time Frame: Up to 8 hours post dose
|
Measured using pulse oximetry
|
Up to 8 hours post dose
|
Part 1: Effect of KUR-101 on respiratory function when compared to placebo
Time Frame: Up to 8 hours post dose
|
Measured using vital signs monitoring
|
Up to 8 hours post dose
|
Part 2: Effect of KUR-101 on respiratory function when compared to placebo and oxycodone
Time Frame: Up to 8 hours post dose
|
Measured using continuous end-tidal capnography monitoring
|
Up to 8 hours post dose
|
Part 2: Effect of KUR-101 on respiratory function when compared to placebo and oxycodone
Time Frame: Up to 8 hours post dose
|
Measured using pulse oximetry
|
Up to 8 hours post dose
|
Part 2: Effect of KUR-101 on respiratory function when compared to placebo and oxycodone
Time Frame: Up to 8 hours post dose
|
Measured using vital signs monitoring
|
Up to 8 hours post dose
|
Part 2: Safety of KUR-101 when compared with placebo and oxycodone
Time Frame: From the signing of the informed consent through Day 22
|
Measured by the incidence of treatment-emergent adverse events
|
From the signing of the informed consent through Day 22
|
Part 2: Addictive potential of KUR-101 when compared with placebo and oxycodone
Time Frame: Up to 4 hours post dose
|
Measured through the Desire for Opioids visual acuity scale
|
Up to 4 hours post dose
|
Part 2: Addictive potential of KUR-101 when compared with placebo and oxycodone
Time Frame: Up to 4 hours post dose
|
Measured through the Addiction Research Center Inventory Morphine Benzedrine Group scale
|
Up to 4 hours post dose
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Part 1: Effect of KUR-101 on evoked pain response as compared to placebo
Time Frame: Day 1 up to 4 hours post dose
|
Measured using the cold pressor test
|
Day 1 up to 4 hours post dose
|
Part 1: Addictive potential of KUR-101 when compared with placebo
Time Frame: Up to 4 hours post dose
|
Measured through the Desire for Opioids visual acuity scale
|
Up to 4 hours post dose
|
Part 1: Addictive potential of KUR-101 when compared with placebo
Time Frame: Up to 4 hours post dose
|
Measured through the Addiction Research Center Inventory Morphine Benzedrine Group scale
|
Up to 4 hours post dose
|
Collaborators and Investigators
Sponsor
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- KUR-101-101
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Acute Pain
-
Rajavithi HospitalCompletedTotal Abdominal Hysterectomy ,Pain , Acute Postoperative,Gabapentin , CelecoxibThailand
-
Schulthess KlinikNot yet recruiting
-
Seoul National University HospitalNot yet recruiting
-
Chung-Ang University Gwangmyeong HospitalRecruitingPostoperative Pain, AcuteKorea, Republic of
-
TC Erciyes UniversityCompletedPostoperative Pain, AcuteTurkey
-
Umraniye Education and Research HospitalNot yet recruiting
-
Sohag UniversityCompletedPostoperative Pain, AcuteEgypt
-
Northwell HealthRecruitingPain, Postoperative | Postoperative Pain, AcuteUnited States
-
Zagazig UniversityRecruiting
-
Mansoura UniversityRecruitingPostoperative Pain, AcuteEgypt
Clinical Trials on KUR-101
-
Kuros Biosurgery AGAvania; Kuros BioSciences B.V.Active, not recruitingDegenerative Disc Disease | Spinal FusionUnited States
-
Seoul National University HospitalCompleted
-
Hospitalsenheden VestCompleted
-
Athenex, Inc.RecruitingB-cell Lymphoma | CLL/SLL | ALL, Childhood | DLBCL - Diffuse Large B Cell Lymphoma | B-cell Leukemia | NHL, Relapsed, Adult | ALL, Adult B CellUnited States
-
TR TherapeuticsCompleted
-
Brigham and Women's HospitalRecruiting
-
Alaunos TherapeuticsCompleted
-
Abalonex, LLCNot yet recruitingTraumatic Brain Injury | Cerebral Edema
-
Benjamin IzarTerminatedLeiomyosarcoma | LiposarcomaUnited States
-
Flame BiosciencesCompletedHealthy SubjectsUnited States